Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
Hum Vaccin ImmunotherMay 29, 2026 (epub)
Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated the safety and immunogenicity of mRNA-1083, a multicomponent vaccine for influenza and SARS-CoV-2, in adults aged ≥50 years. Results showed that mRNA-1083 maintained hemagglutination inhibition titers and SARS-CoV-2 neutralizing antibody responses through 6 months, with no serious adverse events reported.
Key findings
- mRNA-1083 induced HAI titers that were maintained through 6 months and comparable to or higher than comparator responses.
- SARS-CoV-2 nAb responses remained higher for mRNA-1083 than comparators through 6 months.
- Reactogenicity was predominantly grade 1-2, with similar unsolicited adverse events between groups.
- No serious adverse events or deaths related to vaccination were reported through 6 months.
Why it matters
The findings suggest that mRNA-1083 could provide a durable immune response against both influenza and SARS-CoV-2 in older adults, a population at higher risk for severe outcomes from these infections.